Company intelligence / Profile preview

Onchilles Pharma

San Diego, California, United Statesonchillespharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Onchilles has demonstrated that its lead candidate N17350 selectively kills tumor cells—including chemotherapy-resistant ones—while sparing healthy immune cells. Preclinical data show efficacy across multiple tumor types and patient-derived models. First-in-human clinical trials are planned for late 2025.

Therapeutic areas: Oncology
Modalities: Biologics (protein-based therapeutics)Monoclonal antibodies (for TAM modulation)
Industry: Biotech

Drug pipeline

2 assets

N17350

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Onchilles Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onchilles Pharma.

Explore the full profile